Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VIRILON vs METHYLTESTOSTERONE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Testosterone replacement therapy; binds to androgen receptors, leading to activation of androgen-responsive genes and promotion of male secondary sexual characteristics.
Methyltestosterone is a synthetic androgen that binds to and activates androgen receptors (AR) in target tissues, promoting the development and maintenance of male secondary sexual characteristics and anabolic effects. It also suppresses gonadotropin-releasing hormone (Gn RH) secretion via negative feedback, reducing endogenous testosterone production.
Male hypogonadism (primary and hypogonadotropic),Delayed puberty in males,Off-label: Androgen replacement in transgender men, libido enhancement in women (limited use)
Male hypogonadism (primary or hypogonadotropic),Delayed puberty in males,Metastatic breast cancer in women (palliative therapy),Off-label: Androgen replacement therapy, male contraception, cachexia, and osteoporosis in men
200 mg intramuscularly every 2 weeks for androgen replacement therapy in adult males.
10-50 mg orally once daily or divided twice daily, or 10-25 mg buccally twice daily.
Terminal elimination half-life is approximately 3–4 hours for methyltestosterone; however, the pharmacologic effect persists longer due to active metabolites, supporting once-daily dosing.
2-4 hours (terminal); requires multiple daily dosing or transdermal route due to short half-life.
Primarily hepatic via CYP3A4 and other CYP450 enzymes; metabolites are excreted in urine.
No dose adjustment required for renal impairment. Use with caution in patients with nephrotic syndrome due to potential fluid retention.
No specific guidelines; use caution in severe impairment (Cr Cl <30 m L/min) due to potential fluid retention and increased toxicity.
WARNING: Use in men with breast cancer or known/suspected prostate cancer is contraindicated. Risk of accelerated growth of prostate cancer and exacerbation of breast cancer.
Testosterone esters (e.g., testosterone cypionate, testosterone enanthate) are contraindicated in pregnancy. Androgens can cause virilization of the female fetus, including clitoromegaly, labial fusion, and urogenital sinus abnormalities, especially during the first trimester when genital differentiation occurs. Risk is dose-dependent and increases with higher maternal androgen levels. No adequate human studies; animal studies show teratogenic effects at high doses.
First trimester: Irreversible masculinization of female fetus (clitoral hypertrophy, labial fusion). Second trimester: Continued virilization risk. Third trimester: Potential for clitoral enlargement. Contraindicated in pregnancy.
VIRILON (methyltestosterone) is an androgen used for testosterone replacement therapy. Monitor liver function tests due to risk of hepatotoxicity. Avoid in patients with prostate or breast cancer. May cause priapism, gynecomastia, and edema. Use with caution in elderly due to increased risk of prostatic hyperplasia.
Monitor liver function tests regularly due to risk of hepatotoxicity; avoid in men with prostate or breast cancer; watch for erythrocytosis (check hematocrit); use caution in patients with cardiovascular or renal disease due to fluid retention; potent androgen may cause virilization in women and premature epiphyseal closure in children.
No interactions on record
"Methyltestosterone, a synthetic androgen, may inhibit the hepatic metabolism of doxorubicin via competitive inhibition of CYP3A4, leading to increased plasma concentrations of doxorubicin and its active metabolite doxorubicinol. This elevation potentiates the risk of dose-dependent toxicities, including myelosuppression, cardiotoxicity, and mucositis. Clinically, patients may experience exacerbated adverse effects requiring dose adjustments or alternative therapeutic strategies."
"Rifapentine, a potent inducer of cytochrome P450 (CYP) 3A4 enzymes, significantly increases the hepatic metabolism of Methyltestosterone, a substrate of CYP3A4. This accelerated clearance reduces systemic exposure to Methyltestosterone, potentially diminishing its therapeutic efficacy in androgen replacement therapy. Clinically, patients may experience inadequate testosterone effects, such as persistent hypogonadal symptoms or suboptimal response to treatment."
"Methyltestosterone, an androgen, may decrease the cardiotoxic effects of Ouabain, a cardiac glycoside, by increasing the expression of Na+/K+-ATPase α2 subunits in cardiac myocytes, thereby enhancing the therapeutic index of ouabain. This interaction can lead to a reduced risk of ouabain-induced arrhythmias, but careful monitoring is required as androgen therapy may also alter the pharmacokinetics of ouabain through changes in renal function or volume status."
VIRILON and METHYLTESTOSTERONE are distinct pharmacological agents. VIRILON belongs to the Androgen class and is primarily used for Male hypogonadism (primary and hypogonadotropic)Delayed puberty in malesOff-label: Androgen replacement in transgender men, libido enhancement in women (limited use). METHYLTESTOSTERONE belongs to the Androgen class and is primarily used for Male hypogonadism (primary or hypogonadotropic)Delayed puberty in malesMetastatic breast cancer in women (palliative therapy)Off-label: Androgen replacement therapy, male contraception, cachexia, and osteoporosis in men. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. VIRILON carries a safety status of Category C, whereas METHYLTESTOSTERONE safety is classified as Category D/X. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Primarily hepatic via cytochrome P450 (CYP3A4) oxidation and conjugation (glucuronidation and sulfation). Metabolites include 17-keto steroids and other polar compounds. Excretion is primarily renal.
Approximately 90% of administered methyltestosterone is excreted as glucuronide and sulfate conjugates in urine; less than 5% appears in feces as unchanged drug and metabolites.
Renal (primarily as glucuronide and sulfate conjugates, ~90%); fecal (~10%). Unchanged drug is minimal.
Approximately 95% bound to plasma proteins, primarily sex hormone-binding globulin (SHBG) and albumin.
98% bound to albumin and sex hormone-binding globulin (SHBG).
Apparent volume of distribution is approximately 0.5–1.0 L/kg, indicating distribution into total body water with some tissue binding.
0.5-0.8 L/kg; reflects extensive tissue distribution (e.g., muscle, prostate) and high protein binding.
Oral bioavailability is approximately 40–60% due to extensive first-pass metabolism in the liver. Sublingual administration may achieve higher systemic exposure.
Oral: low (<20%) due to extensive first-pass hepatic metabolism; IM: 100%; Transdermal: ~10% (variation by site); Buccal: ~40-90% depending on formulation.
Contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). For moderate impairment (Child-Pugh Class B), reduce dose to 100 mg every 2 weeks and monitor liver function.
Contraindicated in Child-Pugh class B or C; use reduced dose (e.g., 5-10 mg daily) with close monitoring in mild impairment (Child-Pugh A).
Not recommended for use in pediatric patients. Safety and efficacy have not been established; may cause premature epiphyseal closure and virilization.
Not recommended for growth promotion due to risk of premature epiphyseal closure; dosage for delayed puberty: 2.5-10 mg orally daily for 4-6 months.
Use with caution in elderly patients due to increased risk of prostatic hypertrophy and prostatic carcinoma. Monitor prostate-specific antigen (PSA) regularly. Consider lower starting dose of 100 mg every 2 weeks.
Initiate at lowest dose (e.g., 5-10 mg daily) due to increased risk of prostatic hypertrophy, fluid retention, and androgenic effects.
WARNING: Prolonged use of high doses of androgens has been associated with hepatic adenomas, hepatocellular carcinoma, and peliosis hepatis. Methyltestosterone is also associated with cholestatic hepatitis and jaundice. Women should be monitored for virilization. Androgens are not indicated for enhancement of athletic performance and may cause serious adverse effects.
Take with food to reduce GI upset. Avoid grapefruit juice as it may increase methyltestosterone levels. Alcohol consumption may exacerbate hepatotoxicity.
No specific food interactions; however, avoid excessive alcohol due to hepatotoxicity risk. Maintain a low-sodium diet if fluid retention occurs.
Testosterone is excreted into breast milk in small amounts; M/P ratio is not established. Use in nursing mothers is not recommended due to potential adverse effects on the infant, including virilization and disruption of hormonal balance. Alternative therapies should be considered if breastfeeding is desired.
Excreted into breast milk. M/P ratio unknown. May cause virilization in female infants. Contraindicated during breastfeeding.
Not applicable; use during pregnancy is contraindicated. No dose adjustment studies exist. If inadvertent use occurs, discontinue immediately and monitor for fetal effects. Pharmacokinetic changes during pregnancy (e.g., increased volume of distribution, altered metabolism) would likely require dose adjustments if use were considered, but due to teratogenicity, no safe dosing regimen can be recommended.
Not applicable during pregnancy; contraindicated. No dose adjustment recommendations exist as use is avoided entirely.
Take exactly as prescribed; do not increase dose or frequency.,Report symptoms of priapism (prolonged erection), jaundice, or edema immediately.,Regular blood tests (liver function, PSA, lipid profile) are required.,Avoid alcohol as it may increase risk of liver damage.,Women of childbearing age should use effective contraception due to potential virilization of fetus.,Do not use if you have a history of prostate or breast cancer.
Take exactly as prescribed; do not increase dose without consulting your doctor.,Report signs of liver problems: yellowing skin/eyes, dark urine, abdominal pain.,Women: report hoarseness, acne, hirsutism, or menstrual irregularities immediately.,Men: report any breast enlargement, difficulty urinating, or persistent erections.,Avoid excessive alcohol consumption as it may increase liver damage risk.,Regular blood tests (liver function, cholesterol, hematocrit) are required.,May cause infertility; discuss family planning with your doctor if applicable.,Keep out of reach of children; this medication can cause serious harm.